• Thinly traded cancer therapy developer Arcus Biosciences (
RCUS+83.7%) is up big on almost a 7x surge in volume on
reports that Gilead Sciences (
GILD +2.0%) is mulling a "significant stake" in the company.
• The company's pipeline includes anti-TIGIT antibody AB154, PD-1 inhibitor zimberelimab and dual A2a/A2b adenosine receptor antagonist AB928.
• Alphabet's venture capital unit, GV, is also an investor.